TGFB1 and neuroblastoma: Thus, targeting TGFβ1R1, the most commonly upregulated member of the TGFβ family with Galunisertib might offer a promising strategy to enhance the anti-NB efficacy of Dinutuximab combined with adoptively transferred activated NK cells [164].